7 days ago
Lupin launches generic Lotemax ophthalmic suspension in the U.S. market
Lupin Limited, the global pharmaceutical major, announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States on July 16, 2025.
The product is a generic version of Lotemax® Ophthalmic Suspension, 0.5% by Bausch & Lomb Inc., which recorded annual sales of approximately USD 55 million in the U.S., according to IQVIA MAT (May 2025).
Advertisement
Lupin's generic is indicated for:
Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe (e.g., allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides).
Post-operative inflammation following ocular surgery.
This launch strengthens Lupin's U.S. portfolio in the ophthalmic therapy area and underscores its commitment to providing affordable treatment options in key markets.
Lupin continues to maintain its strong presence in the U.S. generics space while also focusing on complex generics, biotechnology products, and branded formulations globally.
